In that study, patients with metastatic cancer had higher rates of PRT30 in case of lower performance status, liver metastases, brain metastases, bone metastases, pleural metastases (or effusion), leukocytosis, elevated C-reactive protein, more than one cancer diagnosis, progressive disease outside the intended radiotherapy region, pain management with opioids, and ongoing steroid medication. Here, CRP is linked to cancer.